Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Lubiprostone for Prevention of Opioid-Induced Constipation in Cancer Pain
jRCTs051230150Phase 2Recruiting
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cobiprostone in opioid-induced constipation (OIC) and cancer pain. Primary endpoint: Incidence of opioid-induced constipation by ROME IV at 1 week. Started Jan 2025; status: recruiting.
02
Drugs
cobiprostone
03
Conditions
opioid-induced constipation (OIC)cancer pain
Beyond the preview
Go deeper on jRCTs051230150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230150.